Another study showed that the DNA methylation of TOP2B has a typical male bias in bladder cancer, and its related drug valrubicin can be used for intravesical treatment of BCG-refractory bladder carcinoma in situ [30]. The gene discussed is TOP2B; the disease is urinary bladder carcinoma.